Vanguard Global Advisers
UTHR icon

Vanguard Global Advisers’s United Therapeutics UTHR Stock Holding History

Vanguard Global Advisers’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.4M Sell
17,345
-2,148
-11% -$1.21M ﹤0.01% 644
2026
Q1 		$11.6M Buy
+19,493
New +$9.71M 0.01% 598

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Vanguard Global Advisers's UTHR Position: Q2 2026 in Review

Vanguard Global Advisers reduced its United Therapeutics (UTHR) stake by 11% in Q2 2026, selling an estimated $1.21M and leaving 17,345 shares worth $9.4M. The position accounts for ﹤0.01% of the portfolio, ranked #644.

Vanguard Global Advisers first reported a position in UTHR in Q1 2026 and has held it in 2 quarters since. The position peaked at $11.6M in Q1 2026. 858 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Vanguard Global Advisers held 17,345 shares of United Therapeutics worth $9.4M as of Q2 2026.
  • Vanguard Global Advisers sold 2,148 United Therapeutics shares in Q2 2026, an estimated $1.21M.
  • United Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #644 holding.
  • Vanguard Global Advisers first reported a position in United Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's United Therapeutics position peaked at $11.6M in Q1 2026.
  • 858 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.